Literature DB >> 7793889

In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on Toxoplasma gondii.

E Schoondermark-van de Ven1, T Vree, W Melchers, W Camps, J Galama.   

Abstract

Sulfadiazine and the metabolites N4-acetyl-sulfadiazine, 4-OH-sulfadiazine, 5-OH-sulfadiazine, 5-OH-glucuronide-sulfadiazine, and 5-OH-sulfate-sulfadiazine were tested separately and in combination with pyrimethamine for the inhibitory activity on Toxoplasma gondii growth in vitro. Except for N4-acetyl-sulfadiazine, all sulfa compounds possessed anti-Toxoplasma activity. The addition of 0.05 micrograms of pyrimethamine per ml, a concentration which in itself is not inhibitory, potentiated the microbial activity of sulfadiazine and its metabolites 100 fold.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7793889      PMCID： PMC162621          DOI： 10.1128/AAC.39.3.763

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Effect of pyrimethamine and sulfadiazine on the fine structure and multiplication of Toxoplasma gondii in cell cultures.

Authors:  H G Sheffield; M L Melton
Journal:  J Parasitol       Date:  1975-08       Impact factor: 1.276

2.  Anaesthetic research: new approaches need fresh attitudes.

Authors:  N W Goodman
Journal:  Anaesthesia       Date:  1990-11       Impact factor: 6.955

3.  Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate.

Authors:  J A Kovacs; C J Allegra; J C Swan; J C Drake; J E Parrillo; B A Chabner; H Masur
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

4.  Disposition of sulphadiazine in rhesus monkeys.

Authors:  C K Nain; B Sharma; S Mehta
Journal:  Indian J Exp Biol       Date:  1982-01       Impact factor: 0.818

5.  In vitro effects of three new 1,2,4-trioxanes (pentatroxane, thiahexatroxane, and hexatroxanone) on Toxoplasma gondii.

Authors:  H R Chang; C W Jefford; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  In vitro effects of folate inhibitors on Toxoplasma gondii.

Authors:  F Derouin; C Chastang
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

7.  Pharmacokinetics and renal clearance of sulfamethazine, sulfamerazine, and sulfadiazine and their N4-acetyl and hydroxy metabolites in horses.

Authors:  J F Nouws; E C Firth; T B Vree; M Baakman
Journal:  Am J Vet Res       Date:  1987-03       Impact factor: 1.156

8.  Pharmacokinetics, metabolism, and renal clearance of sulfadiazine, sulfamerazine, and sulfamethazine and of their N4-acetyl and hydroxy metabolites in calves and cows.

Authors:  J F Nouws; D Mevius; T B Vree; M Baakman; M Degen
Journal:  Am J Vet Res       Date:  1988-07       Impact factor: 1.156

9.  In vitro antimicrobial activity of hydroxy and N4-acetyl sulphonamide metabolites.

Authors:  J F Nouws; T B Vree; Y A Hekster
Journal:  Vet Q       Date:  1985-01       Impact factor: 3.320

10.  In vitro assessment of antimicrobial agents against Toxoplasma gondii.

Authors:  C Harris; M P Salgo; H B Tanowitz; M Wittner
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226
View more
  6 in total

1.  Structural characterization of sulfadiazine metabolites using H/D exchange combined with various MS/MS experiments.

Authors:  Thomas Pfeifer; Jochen Tuerk; Regine Fuchs
Journal:  J Am Soc Mass Spectrom       Date:  2005-10       Impact factor: 3.109

2.  Use of Toxoplasma gondii expressing beta-galactosidase for colorimetric assessment of drug activity in vitro.

Authors:  D C McFadden; F Seeber; J C Boothroyd
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  Evaluation of drug effects on Toxoplasma gondii nuclear and plastid DNA replication using real-time PCR.

Authors:  Qing Zhao; Ming Zhang; Lingxian Hong; Kefu Zhou; Yuguang Lin
Journal:  Parasitol Res       Date:  2010-02-26       Impact factor: 2.289

4.  Plasma pharmacokinetics of sulfadiazine administered twice daily versus four times daily are similar in human immunodeficiency virus-infected patients.

Authors:  M Kelli Jordan; Aaron H Burstein; Diane Rock-Kress; Raul M Alfaro; Alice K Pau; Joseph A Kovacs; Stephen C Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

5.  Population pharmacokinetics of pyrimethamine and sulfadoxine in children with congenital toxoplasmosis.

Authors:  T Trenque; N Simon; I Villena; C Chemla; C Quereux; B Leroux; R Jaussaud; G Rémy; D Dupouy; H Millart; J-M Pinon; S Urien
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

6.  Effects of Extracts from Thai Piperaceae Plants against Infection with Toxoplasma gondii.

Authors:  Arpron Leesombun; Sookruetai Boonmasawai; Naomi Shimoda; Yoshifumi Nishikawa
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.